Next Treatments
Back to Eczema

BYN-001

TypeInjection StageNo phase reached Latest updateAug 5, 2026Phase 1 study posted

What stands out

New approach in eczema

  • Binds to IL-25, a signal that promotes type 2 immune responses
Derived from NCT07746817 · UniProt Q9H293 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Aug 5, 2026. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Aug 5, 2026Phase 1 trial postedA Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07746817

Sources

Trials